Europe High Intensity Focused Ultrasound (HIFU) Market Analysis & Forecast 2025-2033

Europe High-Intensity Focused Ultrasound Market Size & Forecast 2025-2033

The size of the European High-Intensity Focused Ultrasound Market stood at USD 35.04 billion in 2024 and is expected to grow to USD 65.57 billion by 2033, growing at a CAGR of 7.21% during the period 2025-2033. The market is fueled by growing demand for non-invasive therapeutic treatments, improved imaging technology, and increasing incidence of cancer and uterine fibroids in key countries of Europe.

The report Europe High-Intensity Focused Ultrasound Market & Forecast covers by Imaging Technology (Ultrasound HIFU Therapy, MRI HIFU Therapy), Application (Prostate Cancer, Uterine Fibroids, Neurological Disorders, Aesthetics, Others), End User (Diagnostic Centers, Hospitals, Research Centers, Others), Country and Company Analysis 2025-2033.

Market Overview of Europe High Intensity Focused Ultrasound (HIFU)

High-Intensity Focused Ultrasound is an image-guided non-invasive treatment modality utilizing focused ultrasound energy to create a local heat that destroys the target tissue while leaving surrounding tissue undamaged. With its ability to focus ultrasonic energy on a particular location, HIFU is capable of treating diseases like tumors, fibroids, and even some neurological diseases. HIFU finds extensive applications in oncology in the treatment of prostate, liver, and pancreatic cancers and gynecology for uterine fibroids. In Europe, HIFU has become popular because it is a non-surgical procedure, has short recovery time, and involves less risk of complications.

Growing awareness of minimally invasive treatment, robust healthcare infrastructure, and supportive regulatory initiatives drive its adoption in the region. Germany, France, and the UK are at the forefront of clinical trials and incorporating HIFU in standard medical practice. Constant advances in technology and collaborations between medical device manufacturers and research centers continue to boost the market's growth and adoption among healthcare providers and patients.

Growth Driver in the Europe High-Intensity Focused Ultrasound Market

Growing Demand for Non-Invasive Procedures

Growing demand for non-invasive and minimally invasive procedures is one of the key drivers of HIFU market growth in Europe. Patients and physicians are drawn to methods that minimize surgical risk, hospitalization, and recovery time. HIFU offers a non-surgical alternative for treating conditions like tumors and fibroids, making it a preferred option across several European countries with advanced healthcare systems. In 2020, GLOBOCAN projected 325,000 new cases of colon cancer and 182,000 cases of rectum cancer in Europe, with forecasts of 414,000 and 223,000 cases by 2040. The increased use of minimally invasive procedures, including laparoscopic and robotic surgery, has emerged as the preferred method of treatment for colon cancer, most likely to propel market growth.

Advancements in Imaging and Device Technologies

Technological advances in imaging modalities like MRI and ultrasound have improved the accuracy of HIFU greatly. These advances enable clinicians to see better and target the areas for treatment, lowering complications and enhancing outcomes. Europe is also observing intense interaction among MedTech companies and research institutions, driving development in MRI-guided HIFU systems and real-time monitoring devices, further increasing market uptake. Feb 2025, Royal Philips said that its Radiology Operations Command Center Console has been EU Medical Device Regulation (MDR) certified for remote scanning. The development enables skilled radiologists to guide technologists in real-time, improving the quality of diagnostic imaging and enhancing patient outcomes in Europe.

Growing Applications in Oncology and Aesthetics

The versatility of HIFU across medical disciplines—ranging from oncology to aesthetic dermatology—increases its client base. In Europe, it is found to be used more and more for the treatment of liver and prostate cancers and for face lifting and tightening of skin in the aesthetics market. This vast range of use draws investment from healthcare organizations and clinics and makes the market grow strongly. April 2022, Toosonix A/S has initiated two trials to compile data for the approval of its high-intensity focused ultrasound (HIFU) device in clinical dermatology. On April 19, the firm announced that the first patients were treated with its System One-M device for basal cell carcinoma (BCC).

The Europe High-Intensity Focused Ultrasound Market challenge

High Equipment and Installation Costs

One of the key impediments to HIFU uptake in Europe is the high initial expense of devices and installation. State-of-the-art MRI-guided HIFU systems need to be installed and operated by specialists, which lowers their availability to smaller clinics and hospitals. Such capital limitations impede large-scale deployment, particularly in less developed regions of Europe.

Limited Reimbursement and Clinical Awareness

Even with demonstrated advantages, HIFU continues to have limited reimbursement coverage in a number of European nations. This limits patient access and deters healthcare professionals from providing HIFU therapy. In addition, there is still a shortage of general practitioner familiarity and clinical awareness of HIFU technologies, hindering its uptake into mainstream medical practice.

Europe High-Intensity Focused Ultrasound Market

The European HIFU market is experiencing rapid growth, primarily based on technological advancements, robust healthcare infrastructure, and growing demand for non-invasive treatments. Major nations such as Germany, the UK, and France are spending significantly in enhancing HIFU capacities in public as well as private healthcare segments. Growing use in oncology, gynecology, and cosmetic treatments is expanding the scope of the market. Clinical trials and regulatory clearances are also facilitating quicker adoption throughout the region.

Europe MRI HIFU Market

MRI-guided HIFU is also becoming increasingly important in Europe because of its high accuracy and non-ionizing imaging features. This segment is useful in treating uterine fibroids, bone metastases, and prostate diseases with great precision. European hospitals and research centers are incorporating MRI-HIFU systems into oncology and gynecology units. Development is aided by funding support from healthcare authorities and partnerships with imaging technology companies.

Europe Prostate Cancer High-Intensity Focused Ultrasound Market

HIFU has become a popular choice for localized prostate cancer treatment across Europe, providing a non-surgical approach with few side effects. Its capacity to destroy cancerous tissue while sparing the adjacent structures is being increasingly appreciated. Germany and the UK have made enhanced use of HIFU in urology departments, backed by positive clinical results as well as growing patient and practitioner awareness.

Europe Aesthetics High-Intensity Focused Ultrasound Market

HIFU is increasingly adopted in the aesthetic segment for non-surgical skin lifting, wrinkle reduction, and facial contouring. European consumers are developing increasing interest in cosmetic surgery alternatives that are both safe and effective. Aesthetic clinics throughout France, Italy, and the UK have embraced HIFU equipment for out-of-hospital procedures. The need for youthful look and natural results drives this niche segment ahead.

Europe High-Intensity Focused Ultrasound Hospitals Market

European hospitals are the early adopters of HIFU technology, particularly for oncology, gynecology, and urology procedures. Major healthcare facilities are adding HIFU equipment to their operating rooms for non-invasive treatments. Educational programs and partnerships with equipment companies are also facilitating the adoption of this technology by hospitals. Those nations possessing well-developed public healthcare systems are high-growth hubs for this industry.

Europe High-Intensity Focused Ultrasound Research Centers Market

Research facilities throughout Europe play a crucial role in forging and testing HIFU technologies. Academic institutions and hospitals collaborate in clinical trials aimed at investigating new indications, optimizing treatment protocols, and confirming long-term effectiveness. France, Germany, and the Netherlands are among countries hosting numerous such efforts, enjoying robust government and private investments to promote HIFU-related developments.

France High-Intensity Focused Ultrasound Market

France ranks among the most important European markets for HIFU, helped by its solid healthcare system and research-driven atmosphere. French hospitals are implementing HIFU in the treatment of cancers and fibroids, whereas the aesthetic application is also popular. Government encouragement and clinical trial involvement have placed France as one of the prominent locations for the development and integration of HIFU. Feb 2025, EDAP announced the first patient enrollment in a French clinical trial for the treatment of pancreatic cancer with high-intensity focused ultrasound (HIFU). The open-label, phase I/II study, titled PULS, will initially recruit up to six subjects in phase I to evaluate safety. If the procedure is deemed safe, phase II will recruit a total of 26 subjects to measure efficacy.

Germany High-Intensity Focused Ultrasound Market

Germany has taken the lead in HIFU adoption because of its cutting-edge medical infrastructure and strong focus on precision medicine. German hospitals are making HIFU part of routine care for prostate and liver cancers, as well as aesthetic treatments. High health technology funding, in conjunction with university-medical device company collaborations, drive growth and innovation in the HIFU field. April  2024 –Insightec, a multinational healthcare company, has introduced the CE clearance and European availability of Exablate Prime, a next-generation version of the Exablate Neuro system. Derived from more than 10 years of R&D and customer input, Exablate Prime improves accuracy, performance, and the overall experience for both patients and surgeons.

United Kingdom High-Intensity Focused Ultrasound Market

The UK market for HIFU is growing strongly with expanding use in private and public hospitals. National Health Service (NHS) hospitals are adopting HIFU for cancer and fibroid treatment, aided by increasing clinical evidence and patient demand. The aesthetic market is also growing, with clinics providing HIFU-based facelifts. Government funding in non-invasive treatments further boosts the industry growth. January 2023 – The UK Focused Ultrasound Foundation (UK FUSF) has launched to promote the development and use of focused ultrasound technology in the UK. This novel approach utilizes ultrasound energy guided by real-time imaging to treat deep tissues without surgery or radiation.

Europe HIFU Market Segmentation

Imaging Technology

• Ultrasound HIFU Therapy
• MRI HIFU Therapy

Application

• Prostate Cancer
• Uterine Fibroids
• Neurological Disorders
• Aesthetics
• Others

End User

• Diagnostic Centers
• Hospitals
• Research Centers
• Others

Country

• France
• Germany
• Italy
• Spain
• United Kingdom
• Belgium
• Netherlands
• Russia
• Poland
• Greece
• Norway
• Romania
• Portugal
• Rest of Europe

Companies have been covered from 4 viewpoints

• Overviews
• Key Person
• Recent Developments
• Revenue

Competitive Landscape & Key Players

• Koninklijke Philips N.V.
• EDAP TMS S.A
• Johnson & Johnson
• Medtronic Plc.
• Hitachi Ltd.
• Theraclion
• Stryker
• General Electrics

Report Details: